Lineage Cell Therapeutics, Inc. Common Stock (LCTX) R&D Expenses & History | Stock Alarm

Demo Sign up Log In

Lineage Cell Therapeutics, Inc. Common Stock · R&D Expenses

LCTX R&D Expenses

Latest reported$20.52Mperiod endingJun 30, 2026

LCTX R&D Expenses ($0.00 → $20.52M)

Annual R&D Expenses

High-resolution chart · PNG

LCTX r&d expenses history

Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Lineage Cell Therapeutics, Inc. Common Stock R&D Expenses — Annual fiscal periods (USD)
Period ending	R&D Expenses (USD)
Dec 31, 2025	17,729,000
Dec 31, 2024	12,472,000
Dec 31, 2023	15,705,000
Dec 31, 2022	13,987,000
Dec 31, 2021	33,914,000
Dec 31, 2020	12,317,000
Dec 31, 2019	17,948,000
Dec 31, 2018	20,955,000
Dec 31, 2017	24,024,000
Dec 31, 2016	36,106,000
Dec 31, 2015	42,604,000
Dec 31, 2014	37,532,624
Dec 31, 2013	26,609,423
Dec 31, 2012	18,116,688
Dec 31, 2011	13,699,691
Dec 31, 2010	7,892,024
Dec 31, 2009	2,968,987
Dec 31, 2008	1,706,214
Dec 31, 2007	967,864
Dec 31, 2006	1,422,257
Dec 31, 2005	1,525,686
Dec 31, 2004	1,123,261
Dec 31, 2003	903,018
Dec 31, 2002	1,103,490
Dec 31, 2001	1,685,168
Dec 31, 2000	3,362,841
Dec 31, 1999	4,900,521
Dec 31, 1998	1,700,000
Jun 30, 1998	2,100,000
Jun 30, 1996	0
Jun 30, 1995	1,800,000
Jun 30, 1994	800,000
Jun 30, 1993	0
Jun 30, 1992	0

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.